Identification of drug modulators targeting gene-dosage disease CMT1A.
about
A brief review of recent Charcot-Marie-Tooth research and prioritiesFirefly Luciferase in Chemical Biology: A Compendium of Inhibitors, Mechanistic Evaluation of Chemotypes, and Suggested Use As a ReporterProfile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assaysCollaboration for rare disease drug discovery researchRecommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy.Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-tooth disease.Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene.Tead1 regulates the expression of Peripheral Myelin Protein 22 during Schwann cell development.PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies.Caveats in the Established Understanding of CMT1A.The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A.PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker.Genomic disorders 20 years on-mechanisms for clinical manifestations.Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer
P2860
Q27012700-23140917-73FE-4B86-B2AC-D3A93D9F75EFQ27671683-34C8268C-A3E5-4123-A863-F31C2F01298AQ28487785-E450BB12-0473-4DBD-8F38-9E059048E9BCQ28650560-22E7F5B3-1B17-4FC7-8109-6D042EAEE7F6Q33622527-54CC534F-5386-4595-A397-F166711ED3C6Q34576213-DD90522F-4127-435D-8113-3C165CB7B1A5Q35756877-B6C08F2B-931A-4177-BEA6-A1E4F1B34C01Q36276587-4C1ADC32-8278-4EC0-9FA0-2BDB5DC0CC9FQ37530126-953735D4-AD5D-4765-A4E9-010AC1AD5305Q37715520-6335AA16-4A39-4427-AE12-BD884BAD7789Q41357926-45D5AA15-70BE-48CB-86DB-A812764A393BQ42443417-CF64E6C2-A241-4FD0-A84E-C3BFBB9F4941Q45222726-ACC7F82D-BC9F-4A33-997D-3A492B98DE6EQ46300376-964DDED6-D14F-4FF4-A8BA-B2B7AB08D921Q57961452-37326A9E-F824-4F55-B0CB-D96E865F2998
P2860
Identification of drug modulators targeting gene-dosage disease CMT1A.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Identification of drug modulators targeting gene-dosage disease CMT1A.
@ast
Identification of drug modulators targeting gene-dosage disease CMT1A.
@en
type
label
Identification of drug modulators targeting gene-dosage disease CMT1A.
@ast
Identification of drug modulators targeting gene-dosage disease CMT1A.
@en
prefLabel
Identification of drug modulators targeting gene-dosage disease CMT1A.
@ast
Identification of drug modulators targeting gene-dosage disease CMT1A.
@en
P2093
P2860
P356
P1433
P1476
Identification of drug modulators targeting gene-dosage disease CMT1A.
@en
P2093
Camila Lopez-Anido
James Inglese
Ryan MacArthur
Sung-Wook Jang
P2860
P304
P356
10.1021/CB300048D
P50
P577
2012-05-02T00:00:00Z